Intertek, which provides a wide range of testing services for OINDPs, has announced a new partnership with particle engineering specialist CrystecPharma for creation of a “fast to clinic” development platform for dry powder inhaler formulations. The company says that as of January 2025, the new platform will halve the time typically required to develop DPI formulations through to clinical manufacturing, including both small molecules and biologics.
In 2019, Intertek established a Centre of Excellence for the development of inhaled and nasal drugs at its campus in Cambridge, UK. Earlier this year, the company joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) as an associated member. CrystecPharma’s pipeline includes inhaled dry powder formulations for various indications, including asthma/COPD, malaria, incontinence, IPF, and women’s health.
Intertek Commercial Director Chris Vernall commented, “Combining the proprietary mSAS technology and the speed of early development that partnering with CrystecPharma affords, with the GMP manufacturing and analytics expertise at Intertek, provides the market with an unparalleled service in this area. This unique platform will enable highly effective, stable and safe DPI medicines to be developed and brought to market in a fraction of the time previously possible.’’
CrystecPharma CEO Paul Thorning said, “The strength of our award-winning mSAS technology and Intertek’s expertise in analytical development and GMP clinical manufacturing creates unique opportunities to develop innovative, high-performing medicines and improved treatments for patients.”
Read the Intertek press release.
